Inspyr Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2012
2013
2014
2015
2016
2017
Cost of Goods Sold (COGS) incl. D&A
21.00
23.00
23.00
21.00
21.00
40
Gross Income
21.00
23.00
23.00
21.00
21.00
40
SG&A Expense
6,854.00
6,372.00
6,975.00
6,046.00
3,169.00
3,320
EBIT
6,875.00
6,395.00
6,998.00
6,067.00
3,190.00
3,360
Unusual Expense
50.00
1,096.00
-
181.00
2,523.00
2,506
Interest Expense
-
3.00
-
-
2,888.00
5,234
Pretax Income
6,920.00
5,302.00
6,994.00
5,886.00
3,555.00
11,100
Consolidated Net Income
6,920.00
5,302.00
6,994.00
5,886.00
3,555.00
11,100
Net Income
6,920.00
5,302.00
6,994.00
5,886.00
3,555.00
11,100
Net Income After Extraordinaries
6,920.00
5,302.00
6,994.00
5,886.00
3,555.00
11,100
Net Income Available to Common
6,920.00
5,302.00
6,994.00
5,886.00
3,555.00
13,304
EPS (Basic)
9.52
6.41
6.90
5.10
2.55
2.74
Basic Shares Outstanding
726.80
827.20
1,013.80
1,179.30
1,394.10
4,855.80
EPS (Diluted)
9.52
6.41
6.90
4.99
2.55
2.74
Diluted Shares Outstanding
726.80
827.20
1,013.80
1,179.30
1,394.10
4,855.80
EBITDA
6,854.00
6,372.00
6,975.00
6,046.00
3,169.00
3,320
Non-Operating Interest Income
5.00
-
4.00
-
-
-
About Inspyr Therapeutics
View Profile
